Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philadelphia chromosome positive acute lymphoblastic leukaemia

- PMLiVE

Interview: Harvey Berger and Timothy Clackson, Ariad

Ariad’s CEO and president of R&D talk about following their own path in oncology

- PMLiVE

Ariad halts patient enrolment for cancer drug studies

Concerns raised after patients taking Iclusig experience blood clots and cardiovascular events

- PMLiVE

Gilead halts leukaemia study on positive results

Idelalisib provides significant benefit in chronic lymphocytic leukaemia

Bristol-Myers Squibb (BMS) building

BMS says it defends Sprycel patent in India

Blocks attempts to issue compulsory license for leukaemia drug

National Institute for Health and Care Excellence NICE logo

Pfizer faces NICE rejection for cancer drug Bosulif

Draft guidance says drug is not cost-effective in chronic myeloid leukaemia

- PMLiVE

Ariad gets EU green light for leukaemia drug Iclusig

EC approves drug in two forms of the blood cancer

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

EU recommendations for Gilead, Ariad and Baxter drugs

EMA backs use of HyQvia, Iclusig and Stribild

- PMLiVE

Jonathan Dickinson joins Ariad from BMS

Will lead launch of chronic myeloid leukaemia treatment Iclusig

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Boehringer takes leukaemia drug volasertib into phase III

Shows positive results in a difficult-to-treat patient population

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links